CD4 and cervical cancer: The heterogeneity observed might be due to higher efficacy of the bivalent vaccine against cervical cancer possibly related to the specific adjuvant used (ASO4 adjuvant system), as suggested in two recent immune response head-to-head studies that consistently showed a higher neutralizing antibody production [38, 39] and a higher CD4+ T cell response [38] in bivalent than in quadrivalent vaccine recipients.